Ziftomenib

Research use only, not for human use.

Ziftomenib (KO-539) is an inhibitor of menin-MLL interaction with antitumor activity, suitable for leukemia research.

Ziftomenib (KO-539) is an orally active menin-MLL interaction inhibitor with antitumor activities (WO2017161028A1, compound 151).

The mixed-lineage leukemia (MLL) protein is a histone methyltransferase critical for the epigenetic regulation of gene transcription. Many acute leukemias, including acute myeloblastic leukemia (AML), acute lymphoblastic leukemia (ALL) and mixed-lineage leukemia (MLL), are characterized by the presence of chimeric MLL fusion proteins that result from chromosomal translocations of the MLL gene located at chromosome 11, band q23 (11q23). MLL fusion proteins lack the original histone methyltransferase activity of the C-terminus of MLL and gain the ability to regulate transcription of numerous oncogenes, including HOX and MEIS1, resulting in increased cell proliferation and decreased cell differentiation, ultimately leading to leukemogenesis.

——

——

Others

Other Targets

Histone Methyltransferase

——

——

2134675-36-6

717.871

C33H42F3N9O2S2

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (139.30 mM; Ultrasonic )

CNc1nc(NC2CCN(Cc3ccc4n(C[C@H](C)N5CCN(CC5)S(C)(=O)=O)c(cc4c3C)C#N)CC2)c2cc(CC(F)(F)F)sc2n1

——

(-20℃)

With Ice Pack

≥ 2 years